Pharmaceutical Partnerships, Licensing, Investments and M&A Deals and Trends - March 2020 -

DUBLIN--()--The "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report has been added to's offering.

This report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020.

The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from the publisher's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.


  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Key Topics Covered:

1. Table of Contents

List of Tables

List of Figures

2. Deal Values in Pharmaceutical and Healthcare Industry Increased in March 2020

2.1. Pharmaceuticals & Healthcare, Deals Summary, March 2020

3. Pharmaceuticals & Healthcare, Global, Deal Summary,

3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2020

3.2. Pharmaceuticals & Healthcare, Global, Major Deals, March 2020

3.2.1. Thermo Fisher Scientific to Acquire Qiagen

3.2.2. Gilead Sciences Acquires Forty Seven

3.2.3. Silence Therapeutics Enters into Collaboration with AstraZeneca

3.2.4. CytomX Therapeutics Enters into Agreement with Astellas Pharma

3.2.5. Pfizer Raises USD1.25 Billion in Public Offering of 2.625% Notes Due 2030

3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2020

3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2020

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2020

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

7. Deal Summary by Geography

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors

9. Further Information

9.1. Methodology

9.2. About the Publisher

9.3. Contact the Publisher

9.4. Disclosure information

9.5. Disclaimer

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900